PRE Prenetics: Price-to-Projected Revenue Ratio

Prenetics Global (PRE) ensures high profitability through the express delivery of biological samples to laboratories. The forward P/S trend clearly demonstrates the risk of overpaying for the asset, while 1.80 reflects the latest metric value. Growth is driven by demand for personalized medicine in Asia, and an optimized transportation network completely eliminates diagnostic delays.

Prenetics Global Ltd - PRE Market Cap to Future Revenue Ratio (period 04/28/2023 - 11/13/2026)

Analytical breakdowns for Prenetics Global

- current price and projected stock value:

Stock Price Prenetics|PRE - Average Forecast Price

- company stock capitalization data:

Market Value Prenetics Global|PRE - Business Value

- book value of equity indicators:

Book Value per Share Prenetics|PRE - Total Stockholders' Equity|Market Cap to Net Assets Ratio prenetics.com|PRE - Aggregate Business Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

PRE - Annual Net Income|Expected Profit Prenetics Global|PRE - Price to Earnings Ratio|Future Price to Earnings Prenetics|PRE - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Prenetics Global|PRE - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Prenetics|PRE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months prenetics.com|PRE - Earnings per share growth in current year|Net earnings per share growth forecast for next year Prenetics Global

- revenue and sales details:

PRE - Company Annual Revenue|Company Projected Revenue Prenetics|PRE - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Prenetics Global

Analysis of all company metrics:PRE (Prenetics Global Ltd)

Prenetics Global (PRE) maintains a dominant position in Asian genetics, driven by CircleDNA patents and stringent regulatory barriers. The GURU.Markets tool for calculating the business's future P/S allows for the comparison of projected revenue with gross margin, filtering out market noise; an increase in this multiple indicates expectations of expansion, yet warns the investor of the risk of overpaying for the asset.

Analysis of competing companies

Forward P/S Multiple A (Agilent)|Quest Diagnostics Inc. (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS (Exact Sciences Inc.) - Market Cap to Projected Revenue|RVTY: Forward P/S Multiple|Market Cap to Future Revenue Ratio bio-rad.com (BIO)|Forward Price-to-Revenue Multiple NNNN|SHC (Sotera Health Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple QDEL|Market Cap to Expected Sales Ratio OPKO Health Corp.|Forward P/S Multiple CDNA (CareDx, Inc)|MRVI - Forward Price-to-Revenue Multiple|FLGT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Standard BioTools Inc LAB|CTKB (Cytek Bio) - Forward Price-to-Revenue Multiple|OraSure Corp - Forward Price to Sales|XGN (Exagen Inc) - Forward P/S Multiple|MDXH - Projected Price to Revenue|Price-to-Projected Revenue Ratio Lucid Diagnostics (LUCD)|Price-to-Projected Revenue Ratio IMDX (imdxinc.com)|Price-to-Projected Revenue Ratio Trinity Biotech TRIB|ProPhase Labs Corp (PRPH) - Market Cap to Future Revenue Ratio|Ainos, Inc. - Forward P/S Multiple|CODX: Price-to-Projected Revenue Ratio|HSCS: Forward P/S Multiple|Biomerica Inc. (BMRA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cardio Diagnostics Holdings Inc.|Price-to-Projected Revenue Ratio ONCO|Price-to-Projected Revenue Ratio Virax Biolabs Group (VRAX)|BJDX: Future Price to Revenue|Price-to-Projected Revenue Ratio Aspira Women's Health Inc. AWH|Forward Price to Sales AXDX|centogene.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Enzo Biochem, Inc.|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Genetic Technologies Limited|ME (23andMe) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Psychemedics Corp. PMD